Scarica l'app Stockscreener
150.75
1.44%
2.14
Dopo l'orario di chiusura:
150.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$148.61
Aprire:
$150.47
Volume 24 ore:
1.21M
Relative Volume:
0.55
Capitalizzazione di mercato:
$287.65B
Reddito:
$54.72B
Utile/perdita netta:
$14.02B
Rapporto P/E:
20.98
EPS:
7.1855
Flusso di cassa netto:
$15.32B
1 W Prestazione:
+0.63%
1M Prestazione:
-9.65%
6M Prestazione:
+23.33%
1 anno Prestazione:
+36.57%
Intervallo 1D:
$150.15
$151.78
Intervallo di 1 settimana:
$145.29
$151.78
Portata 52W:
$97.72
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.75 | 283.57B | 54.72B | 14.02B | 15.32B | 7.1855 |
LLY
Lilly Eli Co
|
916.31 | 806.39B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.93 | 566.67B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.18 | 362.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.37 | 287.71B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
187.14 | 288.11B | 58.80B | 10.24B | 8.98B | 3.2788 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Argus | Hold → Buy |
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Novartis AG stock surges on Bank of America price target hike amid strong pharma pipeline momentum - AD HOC NEWS
Novartis AG Stock Faces Pressure Amid Multi-Billion Oncology Acquisition and Pipeline Advances - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug - Sahm
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
NVS Stock Quote Price and Forecast - CNN
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrade and Portfolio Shifts - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Pharma Sector Shifts - AD HOC NEWS
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis slides as shares trade ex-dividend for annual payout - Quiver Quantitative
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Skeletal Dysplasia Market - GlobeNewswire Inc.
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis Stock: Can New Cancer Bets Keep Beating Big Pharma? - AD HOC NEWS
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Novartis stock hits all-time high at 167.87 USD - Investing.com
Novartis stock hits all-time high at 167.87 USD By Investing.com - Investing.com UK
Novartis India shares surge after Swiss parent agrees $159 mln exit deal - Investing.com India
Stocks To Watch, February 20: Swiggy, IT stocks, crude-sensitive stocks, Novartis India, ABB India, CIE Automotive, Zydus Life - Upstox
Where is Novartis AG (NVS) Headed? - Finviz
Nature - Novartis
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
Itchy Skin Conditions? Novartis' Pivotal Trial Success Shows Potential For Targeted Relief - Sahm
A Look Into Novartis Inc's Price Over Earnings - Sahm
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IgA Nephropathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - Barchart.com
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):